Browse DNASE1L3

Summary
SymbolDNASE1L3
Namedeoxyribonuclease I-like 3
Aliases DNAS1L3; LSD; DNase gamma; DHP2; SLEB16; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I-li ......
Chromosomal Location3p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Endoplasmic reticulum Secreted Note=Translocates from the endoplasmic reticulum to the nucleus during apoptosis (PubMed:23229555). Contradictory reports exist about the subcellular localization under normal physiological conditions. Under conditions of cell death, may diffuse and/or be actively transported to the nucleus.
Domain PF03372 Endonuclease/Exonuclease/phosphatase family
Function

Has DNA hydrolytic activity. Is capable of both single- and double-stranded DNA cleavage, producing DNA fragments with 3'-OH ends (By similarity). Can cleave chromatin to nucleosomal units and cleaves nucleosomal and liposome-coated DNA (PubMed:9070308, PubMed:9714828, PubMed:14646506, PubMed:10807908, PubMed:27293190). Acts in internucleosomal DNA fragmentation (INDF) during apoptosis and necrosis (PubMed:23229555, PubMed:24312463). The role in apoptosis includes myogenic and neuronal differentiation, and BCR-mediated clonal deletion of self-reactive B cells (By similarity). Is active on chromatin in apoptotic cell-derived membrane-coated microparticles and thus suppresses anti-DNA autoimmunity (PubMed:27293190). Together with DNASE1, plays a key role in degrading neutrophil extracellular traps (NETs) (By similarity). NETs are mainly composed of DNA fibers and are released by neutrophils to bind pathogens during inflammation (By similarity). Degradation of intravascular NETs by DNASE1 and DNASE1L3 is required to prevent formation of clots that obstruct blood vessels and cause organ damage following inflammation (By similarity).

> Gene Ontology
 
Biological Process GO:0000737 DNA catabolic process, endonucleolytic
GO:0006308 DNA catabolic process
GO:0006309 apoptotic DNA fragmentation
GO:0006921 cellular component disassembly involved in execution phase of apoptosis
GO:0010623 programmed cell death involved in cell development
GO:0019439 aromatic compound catabolic process
GO:0030262 apoptotic nuclear changes
GO:0034655 nucleobase-containing compound catabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0046700 heterocycle catabolic process
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:0097194 execution phase of apoptosis
GO:1901361 organic cyclic compound catabolic process
Molecular Function GO:0004518 nuclease activity
GO:0004519 endonuclease activity
GO:0004520 endodeoxyribonuclease activity
GO:0004536 deoxyribonuclease activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolDNASE1L3
Namedeoxyribonuclease I-like 3
Aliases DNAS1L3; LSD; DNase gamma; DHP2; SLEB16; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I-li ......
Chromosomal Location3p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DNASE1L3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolDNASE1L3
Namedeoxyribonuclease I-like 3
Aliases DNAS1L3; LSD; DNase gamma; DHP2; SLEB16; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I-li ......
Chromosomal Location3p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DNASE1L3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.63 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolDNASE1L3
Namedeoxyribonuclease I-like 3
Aliases DNAS1L3; LSD; DNase gamma; DHP2; SLEB16; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I-li ......
Chromosomal Location3p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DNASE1L3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.0820.12
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.1960.318
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.0060.304
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2850.52
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3960.711
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1460.913
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0570.945
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4810.686
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7720.55
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5680.703
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1670.566
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5950.0376
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DNASE1L3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDNASE1L3
Namedeoxyribonuclease I-like 3
Aliases DNAS1L3; LSD; DNase gamma; DHP2; SLEB16; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I-li ......
Chromosomal Location3p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DNASE1L3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDNASE1L3
Namedeoxyribonuclease I-like 3
Aliases DNAS1L3; LSD; DNase gamma; DHP2; SLEB16; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I-li ......
Chromosomal Location3p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DNASE1L3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DNASE1L3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDNASE1L3
Namedeoxyribonuclease I-like 3
Aliases DNAS1L3; LSD; DNase gamma; DHP2; SLEB16; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I-li ......
Chromosomal Location3p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DNASE1L3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDNASE1L3
Namedeoxyribonuclease I-like 3
Aliases DNAS1L3; LSD; DNase gamma; DHP2; SLEB16; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I-li ......
Chromosomal Location3p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DNASE1L3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDNASE1L3
Namedeoxyribonuclease I-like 3
Aliases DNAS1L3; LSD; DNase gamma; DHP2; SLEB16; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I-li ......
Chromosomal Location3p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DNASE1L3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDNASE1L3
Namedeoxyribonuclease I-like 3
Aliases DNAS1L3; LSD; DNase gamma; DHP2; SLEB16; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I-li ......
Chromosomal Location3p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DNASE1L3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.